Stablepharma is delighted to announce another new recruit to the Science Team in Spain

Stablepharma is delighted to announce another new recruit to the Science team in Madrid, Spain based at Stablepharma’s CoE in Qube Technology Park. With a Bachelors degree in Chemistry from the Universidad de Los Andes – Venezuela and a Biochemistry Master’s Degree from Harvard University, Daniela Briceño Garcia has more than 15 years’ experience working with drug production, vaccines, antibiotics, analgesics and anti-inflammatories, all to GMP standards.

“Daniela is another great addition to our team in Spain’, said Dr Arcadio Garcia de Castro, Chief Scientific Officer at Stablepharma Spain CoE, ‘she is a Senior R&D Technician with a lot of experience in Assay Development & Validation, Analytical Chemistry and Quality Control in the vaccine area. These are the core skills that we require in the progression of our work with the StablevaX™ brand, as we continue to focus on assay development and validation of ‘fridge-free vaccines”. In addition to these responsibilities, Daniela will manage all document updates and elaboration of progress reports.

StablevaX™ is designed to dramatically enhance the performance of existing and new vaccines. Stablepharma Ltd stands to revolutionise the vaccine industry, by helping shield vaccines from temperature-related deterioration and wastage. StablevaX™ has shown strong in-vitro and in-vivo data on stabilising a range of vaccines, including Tetadif (Td) and naked COVID mRNA.

The team in Madrid has been expanding over the last few months in order to accelerate their work with the StablevaX™ brand, in partnership with several European Pharmaceutical Manufacturers and Universities. Headed by Dr Arcadio Garcia de Castro and Juana de la Torre Arrieta, as Senior R&D Manager, Veronica Daza joined the team in the last quarter of 2021 as a Formulation Manager. Before joining Stablepharma, Veronica specialised as a Pharmaceutical Development Expert in a variety of pharmaceutical companies, such as Insud Pharma.

Our vision is to eliminate the need for refrigeration, provided access to children and adults who are most in need of vaccines and eradicate the costs and failures of the cold-chain’ said Ozgur Tuncer, CEO & Executive Chairman of Stablepharma. ‘Our team is expanding across the board to support our partnerships with European Manufacturer BB-NCIPD Ltd (Bul Bio), the Universities of Strathclyde, Southampton and University Hospital La Paz in Madrid’. ‘These are exciting times for Stablepharma as we progress and gather new data in Q1 2022’. ‘We are delighted to welcome Daniela to the Stablepharma team’, added Özgür Tuncer.


More news and updates

Coulter Partners places Chief Operating Officer at Treadwell Therapeutics, playing an integral role in the company’s evolution

Coulter Partners, the global experts in Executive Search and Leadership Development in Life Sciences, Health, and Tech, recently partnered with Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, and are pleased to announce the placement of J.D. Mowery as Chief Operating Officer (COO).

Innovation community at The Oxford Science Park expands further as companies move into the Hayakawa Building

The innovation community at The Oxford Science Park, one of Europe's leading locations for science and technology companies, continues to expand as firms move into the newly refurbished Hayakawa Building.

Coulter Partners announces two additional appointments in Italy

Coulter Partners announces two additional appointments to its new Milan office. Giulia Bacis joins as Senior Consultant and Anna Senzacqua as Consultant. Together with Francesca Lazzarin, Executive Director, Yasemin Holland, Senior Research Associate and Giuliana Milioto, Research Associate, they make up the Italian team who will enrich the firm’s offering to companies growing from Italian headquarters and those expanding into Italy.

BioIVT to Provide Rare Biosamples for the FNIH Biomarkers Consortium Neurodegenerative Disease Project

BioIVT is sourcing matched sets of cerebrospinal fluid, serum, and plasma from donors afflicted with ALS to further research of neurofilament in the blood as a biomarker for early stages of neurodegeneration.

More within